SCHEMBL5543900

SCHEMBL5543900

[CH2]c1ccccc1NCc1ccc(OC(F)(F)C(F)(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 1/20 0.39
KDR P35968 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 1/20 0.39
CACNA1B Q00975 6/20 0.37
HDAC1 Q13547 2/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
THRB P10828 1/20 0.36
ALOX12 P18054 1/20 0.36
KDM1A O60341 1/20 0.36
HSD17B10 Q99714 1/20 0.35
SCN8A Q9UQD0 1/20 0.34
P2RX7 Q99572 1/20 0.34
GPR39 O43194 1/20 0.34
USP1 O94782 1/20 0.34
WDR48 Q8TAF3 1/20 0.34
PLA2G1B P04054 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536417 0.88 KDM1A (0.46) FLT1KDRMEN1KMT2AHDAC1
SCHEMBL5541454 0.85 ABCB1 (0.43) FLT1KDRMEN1KMT2AGAA
SCHEMBL5544468 0.77 HIF1A (0.51) MEN1KMT2AGAAHDAC1MAPT
SCHEMBL5542641 0.77 EPHX2 (0.47) FLT1KDRMEN1KMT2ACACNA1B
SCHEMBL5543537 0.77 L3MBTL1 (0.44) MEN1KMT2AGAAHDAC1MAPT
SCHEMBL5534733 0.75 KCNH3 (0.45) MEN1KMT2ACACNA1BMAPTKDM4E
SCHEMBL5538885 0.74 HSD17B10 (0.59) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL5544589 0.74 KDM4C (0.48) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL5543549 0.73 KDM5A (0.53) FLT1KDRMEN1KMT2AP2RX7
SCHEMBL2096063 0.72 ALDH1A1 (0.34) MEN1KMT2AMAPTALDH1A1PLA2G1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 FLT1 4640/4885KDR 3886/4885MEN1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.